Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2002 2
2003 4
2004 3
2005 4
2006 7
2007 2
2009 3
2010 1
2012 3
2013 1
2014 12
2015 7
2016 14
2017 11
2018 8
2019 9
2020 10
2021 10
2022 22
2023 16
2024 5

Text availability

Article attribute

Article type

Publication date

Search Results

136 results

Results by year

Filters applied: . Clear all
Page 1
Indocyanine Green-based Nanoprobe for In Vivo Detection of Cellular Senescence.
Baker AG, Hartono M, Ou HL, Bistrović Popov A, Brown EL, Joseph J, Golinska M, González-Gualda E, Marcias D, Ge J, Denholm M, Morsli S, Sanghera C, Else TR, Greer HF, Vernet A, Bohndiek SE, Fruk L, Muñoz-Espín D. Baker AG, et al. Among authors: brown el. Angew Chem Int Ed Engl. 2024 Apr 15:e202404885. doi: 10.1002/anie.202404885. Online ahead of print. Angew Chem Int Ed Engl. 2024. PMID: 38622059
A rapid environmental risk assessment of the Kakhovka Dam breach during the Ukraine conflict.
Spears BM, Harpham Q, Brown E, Barnett CL, Barwell L, Collell MR, Davison M, Dixon H, Elliott JA, Garbutt A, Hazlewood C, Hofmann B, Lanyon J, Lofts S, MacKechnie C, Medinets S, Noble J, Ramsbottom D, Redhead JW, Riera A, Spurgeon DJ, Svendsen C, Taylor P, Thackeray SJ, Turvey K, Wood MD. Spears BM, et al. Among authors: brown e. Nat Ecol Evol. 2024 Mar 18. doi: 10.1038/s41559-024-02373-0. Online ahead of print. Nat Ecol Evol. 2024. PMID: 38499872 No abstract available.
Olaparib plus abiraterone versus placebo plus abiraterone in metastatic castration-resistant prostate cancer (PROpel): final prespecified overall survival results of a randomised, double-blind, phase 3 trial.
Saad F, Clarke NW, Oya M, Shore N, Procopio G, Guedes JD, Arslan C, Mehra N, Parnis F, Brown E, Schlürmann F, Joung JY, Sugimoto M, Sartor O, Liu YZ, Poehlein C, Barker L, Del Rosario PM, Armstrong AJ. Saad F, et al. Among authors: brown e. Lancet Oncol. 2023 Oct;24(10):1094-1108. doi: 10.1016/S1470-2045(23)00382-0. Epub 2023 Sep 12. Lancet Oncol. 2023. PMID: 37714168 Clinical Trial.
136 results